Novartis in political row after denying Belgian toddler comp...

The controversy over Novartis’ ultra-pricey gene therapy Zolgensma has intensified after it allegedly refused to supply the one-off therapy to a sick toddler in Belgium on compassionate gro

bluebird presents long-term data from CALD gene therapy

bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te

Novartis points to Zolgensma long-term benefits amid data sc...

Fallout over Zolgensma data scandal continues for Novartis

US senators blast Novartis for Zolgensma data falsification

US politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data used in the approval of its $2.1 million spinal muscular atrophy (SMA) gene therapy Zolge

Bayer boosts cell therapy pipeline with BlueRock acquisition

Bayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes a treatment for Parkinson’s disease.